One of the German group’s biggest cancer hopes has fallen flat, raising more questions about targeting an apoptosis pathway.

ASCO is fast approaching, but in the meantime Olema will have an important readout.

Three years after licensing in the IAP inhibitor xevinapant Merck KGaA will find out if the deal was worth it.